Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%

50% or greater reduction in seizure frequency · people with focal epilepsy

Losigamone probably leads to higher 50% or greater reduction in seizure frequency compared with placebo (moderate certainty).

1 finding from 1 review

Losigamone add‐on therapy for focal epilepsy 2019 · Cochrane Headline outcomes only
RR 1.76 [1.14, 2.72]
2 studies · 467 participants
Moderate

Treatment withdrawal · people with focal epilepsy

Losigamone probably leads to higher treatment withdrawal compared with placebo (moderate certainty).

1 finding from 1 review

Losigamone add‐on therapy for focal epilepsy 2019 · Cochrane Headline outcomes only
RR 2.16 [1.28, 3.67]
2 studies · 467 participants
Moderate

Proportion of participants experiencing adverse events · people with focal epilepsy

Losigamone showed no clear difference in the proportion of participants experiencing any adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Losigamone add‐on therapy for focal epilepsy 2019 · Cochrane Headline outcomes only
RR 1.34 [1, 1.8]
2 studies · 467 participants
Moderate

Dizziness · people with focal epilepsy

Losigamone probably leads to higher adverse event (dizziness) compared with placebo (moderate certainty).

1 finding from 1 review

Losigamone add‐on therapy for focal epilepsy 2019 · Cochrane Headline outcomes only
RR 3.82 [1.69, 8.64]
2 studies · 467 participants
Moderate